The incidence of anti-IFN antibodies appears to be higher in patients with RRMS treated with recombinant IFNβ1 than in patients with chronic hepatitis C treated with either native or pegylated IFNα2 [149,153,154]. The gene discussed is IFNB1; the disease is chronic hepatitis C virus infection.